文献速递银屑病与炎症性皮肤病

银屑病患者抑郁症状、抑郁症及生物制剂治疗的影响:PSOLAR登记研究

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
PubMed 文献 · J Am Acad Dermatol · 2017-11-06

在PSOLAR登记中,评估中重度银屑病患者抑郁症状发生率及治疗影响。生物制剂、光疗和传统系统治疗的抑郁症状发生率分别为每100患者年3.01、5.85和5.70。与传统治疗相比,生物制剂降低抑郁症状风险(HR 0.76,95%CI 0.59-0.98),光疗无此效应。

要点

  • 生物制剂组抑郁症状发生率低于传统系统治疗和光疗组。
  • 生物制剂较传统治疗降低抑郁症状风险(HR 0.76,95%CI 0.59-0.98)。
  • 光疗未显示降低抑郁症状风险(HR 1.05,95%CI 0.71-1.54)。

核心结论

  • 与传统治疗相比,生物制剂可能降低银屑病患者抑郁症状的发生率。

研究设计与样本

  • 基于银屑病纵向评估与登记(PSOLAR)的研究人群,比较生物制剂、传统系统治疗或光疗队列。
  • 每约6个月评估一次,采用多变量模型确定治疗对风险的影响。

主要发现

  • 抑郁症状发生率:生物制剂每100患者年3.01(95%CI 2.73-3.32),光疗5.85(95%CI 4.29-7.97),传统治疗5.70(95%CI 4.58-7.10)。
  • 与传统治疗相比,生物制剂降低抑郁症状风险(HR 0.76,95%CI 0.59-0.98),光疗无显著影响(HR 1.05,95%CI 0.71-1.54)。
  • 抑郁不良事件发生率:生物制剂每100患者年0.21(95%CI 0.15-0.31),光疗0.55(95%CI 0.21-1.47),传统治疗0.14(95%CI 0.03-0.55),事件数仅37例无法建模。

关键数值与推荐

  • 抑郁症状定义为医院焦虑抑郁量表-抑郁评分≥8。

临床怎么用

  • 对中重度银屑病患者,选择生物制剂可能有助于降低抑郁症状风险。

局限性

  • 登记中对抑郁和混杂因素的捕获不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with psoriasis are at an increased risk for depression. However, the impact of treatment on this risk is unclear. OBJECTIVE: Evaluate the incidence and impact of treatment on depression among patients with moderate-to-severe psoriasis. METHODS: We defined a study population within the Psoriasis Longitudinal Assessment and Registry and measured the incidence of depressive symptoms (Hospital Anxiety and Depression Scale-Depression score ≥8) and adverse events (AEs) of depression within cohorts receiving biologics, conventional systemic therapies, or phototherapy. Patients were evaluated at approximately 6-month intervals. Multivariate modeling determined the impact of treatment on risk. RESULTS: The incidence rates of depressive symptoms were 3.01 per 100 patient-years (PYs) (95% confidence interval [CI], 2.73-3.32), 5.85 per 100 PYs (95% CI, 4.29-7.97), and 5.70 per 100 PYs (95% CI, 4.58-7.10) for biologics, phototherapy, and conventional therapy, respectively. Compared with conventional therapy, biologics reduced the risk for depressive symptoms (hazard ratio, 0.76; 95% CI, 0.59-0.98), whereas phototherapy did not (hazard ratio, 1.05; 95% CI, 0.71-1.54). The incidence rates for AEs of depression were 0.21 per 100 PYs (95% CI, 0.15-0.31) for biologics, 0.55 per 100 PYs (95% CI, 0.21-1.47) for phototherapy, and 0.14 per 100 PYs (95% CI, 0.03-0.55) for conventional therapy; the fact that there were too few events (37 AEs) precluded modeling. LIMITATIONS: Incomplete capture of depression and confounders in the patients on registry. CONCLUSION: Compared with conventional therapy, biologics appear to be associated with a lower incidence of depressive symptoms among patients with psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Strober B, Gooderham M, de Jong EMGJ, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2017. PMID: 29102053. doi:10.1016/j.jaad.2017.08.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。